Humacyte, Inc. Operating Lease, Liability, Noncurrent
Humacyte, Inc. (HUMA) had Operating Lease, Liability, Noncurrent of $500.00 thousand as of 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Noncurrent › Liabilities, Other than Long-Term Debt, Noncurrent
us-gaap:OperatingLeaseLiabilityNoncurrent · last filed 2025-03-31
- 2024-12-31: Operating Lease, Liability, Noncurrent $500.00K.
- 2023-12-31: Operating Lease, Liability, Noncurrent $600.00K.
- 2023-03-31: Operating Lease, Liability, Noncurrent $620.00K.
- 2022-12-31: Operating Lease, Liability, Noncurrent $600.00K; Operating Lease, Liability, Noncurrent as first filed $632.00K.
| Period end | Operating Lease, Liability, Noncurrent | Operating Lease, Liability, Noncurrent as first filed |
|---|---|---|
| 2024-12-31 | $500.00K 10-K · filed 2025-03-31 | |
| 2023-12-31 | $600.00K 10-K · filed 2025-03-31 | |
| 2023-03-31 | $620.00K 10-Q · filed 2023-05-12 | |
| 2022-12-31 | $600.00K 10-K · filed 2024-03-28 | $632.00K 10-K · filed 2023-03-24 |
| 2022-09-30 | $645.00K 10-Q · filed 2022-11-10 | |
| 2022-06-30 | $658.00K 10-Q · filed 2022-08-12 | |
| 2022-03-31 | $670.00K 10-Q · filed 2022-05-13 | |
| 2021-12-31 | $682.00K 10-K · filed 2023-03-24 | |
| 2021-09-30 | $693.00K 10-Q · filed 2021-11-15 | |
| 2020-12-31 | $727.00K 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |